Summary. Isolated theca cells (2 \m=x\ 105/ml) were pre-incubated for 1 h in the presence or absence of clomiphene citrate (10\ m=-\ 12\ p=n-\ 10\ m=-\ 4 m). Ovine LH (50 ng/ml) was added and cells were incubated for an additional 3 h. A 50% inhibition of LH-stimulated androstenedione and oestrogen production was obtained with doses of 10\m=-\8m and 2 \m=x\10\m=-\7 m clomiphene, respectively. Furthermore, the effect of clomiphene on LH-stimulated androstenedione production was reversed by washing clomiphene from the cells before stimulation with LH. In subsequent experiments, the effects of clomiphene on C17\p=n-\20-lyase and aromatase activities were examined. 
Introduction
Clomiphene citrate is one of the drugs most commonly used to induce ovulation in anovulatory women. Clinical studies have demonstrated that clomiphene induces ovulation in 80% of anovula¬ tory women, but results in only a 40% pregnancy rate (Speroff et al, 1983) . The discrepancy between rates of ovulation and pregnancy has led investigators to examine the effects of clomiphene more intensely. It is generally accepted that clomiphene exhibits oestrogenic and antioestrogenic effects and induces ovulation in a complex fashion. There are believed to be 3 sjtes of action (Adashi, 1984) . The primary site is the hypothalamus, where clomiphene blocks the negative feed¬ back of oestrogen, thereby enhancing release of gonadotrophins. Secondary sites are the pituitary, where it enhances the GnRH-stimulated release of FSH, and the ovary, where its effects are not completely clarified.
Clomiphene inhibits progesterone synthesis in rat follicles (Laufer et al, 1982) and granulosa cells (Welsh et al, 1984) , monkey luteal cells (Westfahl & Resko, 1983) and hen granulosa cells (Sgarlata et al, 1984) . In contrast, the effects of clomiphene on oestrogen biosynthesis in vitro have been less consistent. Some investigators report a stimulation (Zhuang et al, 1982; Welsh et al., 1984) , and others an inhibition (Laufer et al., 1982) . The effect of clomiphene on androgen synthesis has not been reported.
In an effort to understand further the actions of clomiphene on ovarian steroidogenesis, we investigated the in-vitro effects of clomiphene on androgen and oestrogen production by theca cells from maturing ovarian follicles of the domestic hen. The domestic hen has only one functional ovary and ovulâtes daily for several consecutive days. The maturing yolk-filled follicles are arranged in a size hierarchy according to proximity to ovulation. Production of oestrogen and androgen by the preovulatory follicles occurs exclusively in the theca compartment and is influenced by LH and by the stage of follicular development. Furthermore, these cells contain C17-20-lyase and aromatase (Armstrong, 1984) activities. The aromatase and C17-20-lyase activities are greatest in theca cells from the follicles that are 3 and 4 days away from ovulation (Armstrong, 1984; Marrone & Hertelendy, 1983a , b, 1985 .
Materials and Methods

Experimental animals
One (Marrone & Hertelendy, 1983a , b, 1985 . Theca cells were obtained from the third and fourth largest follicles and isolated by collagenase digestion as described previously (Marrone & Hertelendy, 1983a 
Incubations
Incubations were carried out as described previously (Marrone & Hertelendy, 1983a 
Radioimmunoassay
The incubation media and cells were extracted twice with 2 volumes of diethyl ether. The extraction efficiencies for oestrogen and androstenedione were both >95%. The extract was evaporated to dryness and redissolved in ethyl alcohol; 75% of the sample was taken for oestrogen radioimmunoassay and 2-10% was taken for androstenedione radioimmunoassay. Details of the radioimmunoassays for oestrogens and androstenedione have been reported previously . The oestrogen antiserum (provided by Dr . V. Caldwell, Yale University) reacts equally well with oestradiol-17ß and oestrone and has a 10% cross-reactivity with oestriol. The inter-and intra-assay coefficients of variation were determined to be 11% and 5%, respectively, and the sensitivity was 10 pg per tube. The androstenedione antiserum (ANS-22 from Endocrine Sciences, Tarzana, CA) cross-reacts with 1,4-androstadiene-3,17-dione (40%), 5a-and 5ß-androstan-3,17-dione (35%), androsterone and epiandrosterone (4%), androstane (3-5%), 5a-androstan-3,ll,17-trione (2-5%), and testosterone (2%). The coeffi¬ cients for inter-and intra-assay variation were both 10-11% and the sensitivity of the assay was 5 pg per tube. Samples from each experiment were analysed in the same radioimmunoassay.
HPLC
Samples were extracted with diethyl ether as above and evaporated to dryness under a gentle stream of nitrogen in a 45°C water bath. The extraction efficiencies of the radioactivity were routinely > 95%. The sample was dissolved in 25 µ HPLC-grade methanol and 20 µ were injected into a 5 µ reversed-phase C18 column (Altex Ultrasphere, 15 cm 4-6 mm). The Determination of the production of each steroid metabolite was based on co-elution of radio¬ activity with a known steroid standard. The radioactivity in each peak was expressed as a per¬ centage of the total radioactivity. Only fractions that had radioactivity twice that of the background level were used for the calculations.
Details of the equipment and separation profile of this solvent system have been reported previously (Marrone & Hertelendy, 1983b , are androstenedione and 17ct,20ß-dihydroxy-4-pregnen-3-one. The peaks of radioactivity represented by the substrate, andostenedione and 17a,20ß-dihydroxy-4-pregnen-3-one in 5 experiments com¬ prised 94 ± 0-8% of the total radioactivity collected in 60 fractions (30 min Armstrong (1984) has shown that oestradiol-17ß is the only product detected after incubation of hen thecal homogenates with tritiated testosterone. In theca cells pretreated with clomiphene, and then incubated with 250 ng testosterone, conversion of testosterone to oestrogen was inhibited (Fig. 3) . Oestrogen production rose significantly after incubation with testosterone. There was no change from control with doses of 10"12 to 10"9M-clomiphene, but a dose-dependent inhibition occurred between 10"7 and 10"4M. Testos¬ terone conversion was significantly inhibited (by 80%) at 10~4M-clomiphene and, when baseline oestrogen values were subtracted, 50% inhibition occurred at a dose of 5 IO"6 M-clomiphene.
To assess whether the inhibitory effects of clomiphene could be reversed, theca cells were preincubated with 10"5 M-clomiphene for 4h, washed three times, and then incubated with or without 50 ng LH/ml for 3 h in the absence of clomiphene. There were no significant differences in androstenedione production between the clomiphene-pretreated or non-pretreated groups after LH treatment. The mean androstenedione values (pg/2 IO5 cells/ml; mean + s.e.m.) of 4 separate experiments were: no clomiphene pretreatment, without LH (98-2 ± 45-3) or with LH (451 ± 680); clomiphene pretreatment, without LH (49-8 ± 20-9) or with LH (360 ± 74-4).
Discussion
This study provides evidence that clomiphene inhibits androstenedione and oestrogen production in hen theca cells in vitro. Clomiphene inhibited LH-stimulated androstenedione and oestrogen production in a dose-dependent manner and, in addition, inhibited both the aromatase and C17-20-lyase enzyme activities. Futhermore, the inhibitory effects of clomiphene on steroidogene¬ sis were reversible. An inhibitory effect of clomiphene on the aromatase activity would obviously result in reduced oestrogen production. Likewise, an inhibitory effect of clomiphene on C17-20-lyase activity could contribute indirectly to a reduction in oestrogen production, by limiting the availability of androgen substrate for aromatization to oestrogen.
The inhibitory effects of clomiphene on ovarian steroidogenesis may have two consequences. First, the reduced oestrogen production may enhance LH secretion. It is believed that clomiphene acts at the level of the hypothalamus to displace oestrogen from its receptors, thereby preventing the negative feedback of oestrogen on gonadotrophin release. As a result, LH secretion is stimu¬ lated. The hypothalamic action of clomiphene could be enhanced by a direct inhibitory effect of clomiphene on oestrogen production. On the other hand, impaired folliculogenesis may be another consequence of a direct inhibitory effect of clomiphene on ovarian steroidogenesis. Appropriate quantities of oestrogen are needed, with gonadotrophins, to stimulate follicular maturation (see Goodman & Hodgen, 1983) . Therefore, an inhibitory effect of clomiphene on oestrogen biosynthesis could impair the process of folliculogenesis.
There are conflicting reports concerning the effects of clomiphene on oestrogen production. Laufer et al. (1982) reported an inhibition of oestrogen production by clomiphene in vitro by rat preovulatory follicles. In contrast, Zhuang et al (1982) and Welsh et al (1984) reported that clomi¬ phene pretreatment in vitro stimulated oestrogen production by rat granulosa cells. In the last two reports, granulosa cells were incubated with clomiphene for 3 days, washed to remove clomiphene, and reincubated with androgen substrate. Oestrogen production was measured after incubation with the androgen substrate, in the absence of clomiphene, and so the 'chronic' effects of clomi¬ phene pretreatment on oestrogen biosynthesis were assessed. During such a long-term exposure, there may be opportunities for clomiphene to induce changes in cell metabolism, e.g. induction of steroidogenic enzymes.
In the present study, the 'acute' effects of clomiphene on steroidogenesis were assessed. Oestrogen production was inhibited during a 4-h incubation in the presence of clomiphene. Furthermore, washing the cells after a 4-h exposure to clomiphene reversed the inhibitory effects of clomiphene on steroidogenesis, apparently indicating that this brief exposure to clomiphene did not have a permanent effect on cell metabolism. The differences in experimental protocol between the studies above and the present study may account for the different effects of clomiphene on oestrogen biosynthesis. Furthermore, we cannot rule out that species differences may account for the different effects of clomiphene on oestrogen biosynthesis in the studies discussed above and in the present study.
There are also conflicting reports concerning the effects of clomiphene treatment on oestrogen production in vivo. Marut & Hodgen (1982) reported that plasma oestrogens decreased during high-dose clomiphene treatment in normally cyclic monkeys despite concurrent elevations of gonadotrophins. Decreased oestrogen concentrations in follicular fluid have also been reported in clomiphene-treated as compared to hMG-treated women (diZerega et al, 1983; Dlugi et al, 1985) . However, other reports have described an increase in oestrogen values during clomiphene treatment in monkeys (Littman & Hodgen, 1985) and women (Wu, 1977; Maxson et al, 1984) .
Clearly, in some circumstances clomiphene can exert inhibitory actions on ovarian steroido¬ genesis. Inhibitory effects of clomiphene in vitro on progesterone biosynthesis have been reported for rat granulosa cells (Welsh et al, 1984) , monkey luteal cells (Westfahl & Resko, 1983) , and rat preovulatory follicles (Laufer et al, 1982) . In addition to the inhibitory effects reported here on the aromatase and C17-20-lyase activities, clomiphene has been found to inhibit progesterone biosynthesis by an effect on the cholesterol side-chain cleavage enzyme, but not on the 3ß-steroid dehydrogenase enzyme activity, in hen granulosa cells (Sgarlata et al, 1984) . Furthermore, an inhibitory effect of clomiphene on cholesterol side-chain cleavage activity was obtained using a mitochondrial preparation of hen granulosa cells (Asem & Hertelendy, 1985) , demonstrating a direct effect of clomiphene on this enzyme. It remains to be determined whether the inhibitory effects of clomiphene on the C17-20-lyase and aromatase enzymes in hen theca cells are mediated by a direct effect of clomiphene on the enzymic reactions. However, since the C17-20-lyase, aromatase, and cholesterol side-chain cleavage enzyme activities are all inhibited by clomiphene, this suggests that clomiphene may act via the same mechanism for each enzyme. The cholesterol side-chain cleavage enzyme, as well as the C17-20-lyase and aromatase enzymes, have in common a cytochrome P-450 as part of their system (Lieberman et al, 1984) . The cytochrome P-450 or other similarities in these enzyme systems may be the site of action of clomiphene citrate.
In various mammalian systems, clomiphene has been found to exert both antioestrogenic and oestrogenic effects (see Adashi, 1984) . The effect of oestradiol-17ß on steroidogenesis by hen theca cells has not been examined and, in the present study, no comparisons were made between the actions of clomiphene and oestradiol-17ß on androstenedione and oestrogen production. We are therefore unable to comment on whether or not the effects of clomiphene that we observed are a result of oestrogenic properties of clomiphene in hen theca cells. However, another study has shown that oestradiol-17ß and clomiphene have different sites of action on the pathway from cholesterol to progesterone in hen granulosa cells (Sgarlata et al, 1984) .
Although we acknowledge that there is a problem in extrapolating in-vitro data from hen ovarian cells to the in-vivo human situation, our results confirm other in-vitro studies done on mammalian tissues which indicate that clomiphene has a direct effect on ovarian steroidogenesis. The present study therefore lends support to the ovary as a secondary site of action in the complex mechanism by which clomiphene induces ovulaton in women.
